01652 FUSEN PHARM
- 1.000
- 0.0000.00%
FUSEN PHARM News
fusen pharm (01652.HK) appointed Yang Yukang as the company secretary
Glory news on September 30th: fusen pharm (01652.HK) announced that Mr. Wang Dimin has resigned from the company as company secretary and authorized representative, effective from September 30, 2024. After Mr. Wang's resignation, the board of directors is pleased to announce that Mr. Yang Yukang has been appointed as the company secretary and authorized representative, effective from September 30, 2024.
FUSEN PHARM: Interim Report 2024
Fusen Pharmaceutical's Unit's Flu Drug Gets China Nod for Clinical Trials
Fusen Pharm (01652.HK): Application for clinical trial of type 1.1 traditional Chinese medicine innovative drug "SY617" approved.
On September 19th, Fusen Pharm (01652.HK) announced that its wholly-owned subsidiary, Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd., has obtained approval from the China National Medical Products Administration for the clinical trial of "SY617" (Approval Number: 2024LP02103). SY617 is primarily used for the treatment of epidemic influenza with the pattern of wind-heat and dampness in traditional Chinese medicine, with symptoms such as fever, heaviness of the head, sore throat, aversion to wind, cough, body aches, chest tightness, epigastric fullness, red tongue with white or greasy coating, and slippery or rapid or floating pulse. According to data from Mi Nei, as of
Express News | Fusen Pharmaceutical - Clinical Trial for ``Sy617'' Approved by Nmpa
With a compound annual growth rate of only 2.6% over the past five years, China's top 100 pharmaceutical companies are entering an adjustment period. How will the industry break through under internal and external pressures?
According to the data from China Meheco Group, in 2023, multiple operation indicators of the pharmaceutical industry's leading companies have declined. The compound annual growth rate of the top 100 pharmaceutical companies in the country in the past five years is only 2.6%, and the industry as a whole has entered the adjustment phase from the initial high-speed growth. Behind the weak growth, the health industry is also undergoing transformation: overseas licensing trades for innovative drugs have reached a new high, and leading companies are accelerating outward expansion...
Founder Securities: the revenue growth rate of the pharmacy sector slows down, and the concentration is expected to accelerate.
The individual account reform of medical insurance has led to a decrease in personal account income, affecting pharmaceutical sales and pharmacy business relying on individual account payments. In 2023, pharmacy medical insurance personal account expenditures decreased by 9%, and this trend is expected to continue in 2024.
Is the chain of pharmacies entering a "mini ice age"? H1 growth rate "downgrades", the industry's high-growth stores may reach turning point.
① The growth rate of sales revenue of all categories in retail pharmacies has slowed down, and the competition in stock continues to intensify. In the first half of this year, it was difficult for major chain pharmacies to increase revenue and profit. ② In the future, the focus of pharmacy competition will shift to commodity extension and services. According to the prediction of Zhongkang Industry Research Institute, the growth rate of pharmaceuticals in all end terminals in 2024 is expected to decrease to 4.9%, a decrease from 2023.
Will you be eliminated if you don't go overseas? In the first half of the year, the proportion of innovative drug outbound business development accounted for about 80% | Industry Dynamics.
①At the 2024 New Investment Conference hosted by Frost Sullivan, the issue of going global was favored by participants. ②There is a new trend in the export of innovative drugs in China, for example, the number of export BDs exceeded License-in for the first time in 2023. ③Some participating experts put forward rational opinions and called for internal strength, not just enthusiasm.
Fusen Pharm (01652): The application for marketing authorization of 'Mei Asartan Potassium Tablets' has been accepted.
Fusen Pharm (01652) announced that its wholly-owned subsidiary, Jiaheng (Zhuhai Hengqin) Medical Technology Co., Ltd., has reached an agreement on...
Express News | Fusen Pharmaceutical - Application for Launching Measartan Potassium Tablets Accepted by Nmpa
Fusen Pharm (01652.HK) has seen a decrease in half-year earnings of approximately 41.6% to 0.196 billion yuan.
Fusen Pharm (01652.HK) announced that the company's income decreased by approximately RMB 41.6% from approximately RMB 3.364 million in the first half of 2023 to approximately RMB 1.963 million in the first half of 2024. Gross profit decreased by approximately RMB 40.9% from approximately RMB 1.791 million in the first half of 2023 to approximately RMB 1.059 million in the first half of 2024. In the first half of 2024, the company's equity holders had a loss of approximately RMB 3.69 million, while in the first half of 2023, there was a surplus of approximately RMB 1.65 million.
Express News | Fusen Pharmaceutical H1 Capex RMB 46 Million
Express News | Fusen Pharmaceutical H1 Gross Profit RMB 105.9 Million
FUSEN PHARM: ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2024
Fusen Pharmaceutical Flags Losses in H1
Fusen Pharm (01652) issues profit warning, with expected mid-year loss of approximately 30 million yuan to 45 million yuan for shareholders, turning from profit to loss on a year-on-year basis.
Fusen Pharm (01652) announced that the group is expected to obtain shareholder's due by June 30, 2024.
Express News | Fusen Pharmaceutical Sees Decrease in Revenue for Six Months
Express News | Fusen Pharmaceutical Sees Loss Attributable RMB30 Mln to RMB45 Mln for Six Months
FUSEN PHARM: PROFIT WARNING
Analysis
Price Target
No Data
No Data